Neurocrine Biosciences
NBIX
#1462
Rank
$12.03 B
Marketcap
$120.69
Share price
3.94%
Change (1 day)
-9.02%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) - Total debt

Total debt on the balance sheet as of December 2024 : $0.45 Billion USD

According to Neurocrine Biosciences 's latest financial reports the company's total debt is $0.45 Billion USD. A companyโ€™s total debt is the sum of all current and non-current debts.

Neurocrine Biosciences - Total debt on balance sheet (from 1996 to 2024)

Total debt by year

Year Total debt Change
2023-12-31$0.42 B62.95%
2022-12-31$0.26 B-40.3%
2021-12-31$0.44 B6.82%
2020-12-31$0.41 B-16.79%
2019-12-31$0.49 B27.54%
2018-12-31$0.38 B5.11%
2017-12-31$0.36 B
2009-12-31$11.53 M-25.12%
2008-12-31$15.39 M936.14%
2007-12-31$1.48 M-97.23%
2006-12-31$53.64 M-9.7%
2005-12-31$59.4 M-10.17%
2004-12-31$66.12 M81.5%
2003-12-31$36.43 M359.14%
2002-12-31$7.93 M39.53%
2001-12-31$5.68 M46.95%
2000-12-31$3.87 M24.84%
1999-12-31$3.1 M3.33%
1998-12-31$3 M87.5%
1997-12-31$1.6 M0%
1996-12-31$1.6 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
$0.67 B 47.76%๐Ÿ‡บ๐Ÿ‡ธ USA
$7.61 B 1,572.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
$0.47 M-99.90%๐Ÿ‡บ๐Ÿ‡ธ USA
$31.11 B 6,737.99%๐Ÿ‡บ๐Ÿ‡ธ USA
$71.07 B 15,518.33%๐Ÿ‡บ๐Ÿ‡ธ USA
$66.61 B 14,537.88%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.62 B 37.41%๐Ÿ‡บ๐Ÿ‡ธ USA
$18.57 M-95.92%๐Ÿ‡บ๐Ÿ‡ธ USA